Headache Clinical Trial
Official title:
A Randomized Controlled Study of Transcranial Magnetic Stimulation for Postoperative Headache in Patients With Growth Hormone(GH) Pituitary Tumor
Verified date | August 2020 |
Source | Huashan Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Headache is a very common main complaint of patients with GH pituitary tumor, which has seriously affected the normal work and life of patients. Although the current surgery and drugs have a certain effect on patients with headache, the overall effect is not satisfied. However, the use of COX-2 inhibitors, non-steroidal anti-inflammatory drugs and other analgesics are only effective for some patients with headaches, and long-term use has adverse reactions. Therefore, it is necessary to seek new treatments for postoperative headaches in patients with GH pituitary tumors. Transcranial magnetic stimulation (TMS) modulates the excitability of the underlying cerebral cortex by applying a rapidly changing magnetic field on the surface of the scalp. It is a relatively simple and safe method. It is currently approved for treating depression, migraine, obsessive-compulsive disorder, and Alzheimer's disease. Several small clinical studies have proven that rTMS can be used to prevent and treat Headache. Therefore, this study aims to observe the efficacy and safety of TMS in the treatment of postoperative headache in patients with GH pituitary tumors.
Status | Not yet recruiting |
Enrollment | 200 |
Est. completion date | September 30, 2022 |
Est. primary completion date | September 30, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Patients with GH tumor who have undergone transnasal pituitary tumor resection or craniotomy for pituitary tumor resection in the past (3 months or more), aged between 18 and 60 years old, regardless of gender; - Preoperative glucose tolerance test (OGTT) simultaneously determines that the trough value of GH is greater than 1ng/ml, and the level of IGF-1 is greater than the upper limit of the age-sex-matched normal value; ?. Biochemical remission is achieved after surgery, that is, the random GH value is less than 1ng/ml, and the IGF-1 level is within the normal range of age and gender matching; ?. The patient still has headaches after the operation, the duration of each attack is more than 4 hours, and the attack is more than 3 times per month; ?. The patient is in a headache attack period; ?. A clear consciousness, able to understand and sign an informed consent form. Exclusion Criteria: - Patients who are being treated with somatostatin and bromocriptine; - Patients with other intracranial organic diseases; - Pregnant women and children who cannot express; - Patients with other malignant tumors; - Participate in other clinical research in the same period; ?. Patients with severe medical complications, such as heart, lung, kidney, liver and other diseases, severe hypertension or poor blood pressure control, hyperglycemia, blood diseases; - Those with mental illness who cannot cooperate well with the experiment; - Patients with acute infection or open wounds; ?. Acetaminophen is contraindicated (hemolytic anemia, severe liver and kidney dysfunction) or allergic to its components; ?. Patients with contraindications to transcranial magnetic stimulation: patients or users who have implanted cardiac pacemakers, implantable defibrillators and neurostimulators together; those who have a history of epilepsy; wear electronic products (such as insulin Pumps, Holter, etc.). |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Huashan Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | changes in the degree of headache | The degree of headache will be measured by the Visual Analog Scale VAS and the scores change before and after 6 months of intervention will be compared among 3 groups | 6 months | |
Primary | the improvement of quality of life(QOL) | Migraine Defect Assessment Questionnaire MIDAS will be used to evaluate QOL. The QOL will be assessed before and after 6 months of intervention and the changes of MIDAS scores will be compared among 3 groups | 6 months | |
Secondary | The decrease of using acetaminophen | During the experiment, patients will be required to record the dosage of acetaminophen they used. Our anticipated secondary outcome is the decreased usage of painkiller in the rTMS treated patients.The total dosage of acetaminophen used in 1st month and the 6th month during the study will be recorded and the changes of the dosage will be compared among the 3 groups. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03472872 -
A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache
|
Phase 4 | |
Withdrawn |
NCT05410366 -
Safe Harbors in Emergency Medicine, Specific Aim 3
|
||
Withdrawn |
NCT02866084 -
Neuromodulation Treatment of Vestibular Migraines
|
N/A | |
Active, not recruiting |
NCT03537573 -
Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care
|
N/A | |
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Not yet recruiting |
NCT04352218 -
Safety Profile of PETALO CVS in the Treatment of Non-thrombotic Internal Jugular Vein Stenosis and Chronic Headache
|
Phase 2 | |
Completed |
NCT02734992 -
Acceptance and Commitment Therapy vs Medical Treatment as Usual Wait-list Control for Primary Headache Sufferers
|
N/A | |
Completed |
NCT01153789 -
Study of Oculomotor Dysfunction Leading to Children Vertigo
|
N/A | |
Completed |
NCT01327118 -
Prostaglandin F2alpha in a Human Headache Model
|
N/A | |
Not yet recruiting |
NCT00969995 -
Identification of Inflammatory Markers in Migraine Patients
|
N/A | |
Not yet recruiting |
NCT00752921 -
Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache
|
Phase 4 | |
Completed |
NCT00212810 -
Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache.
|
Phase 4 | |
Terminated |
NCT00291395 -
PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00263094 -
An End to the Yom Kippur (and Ramadan) Headache
|
N/A | |
Completed |
NCT00135122 -
Prednisolone in the Treatment of Withdrawal Headache in Probable Medication Overuse Headache
|
Phase 3 | |
Completed |
NCT02475005 -
An Intervention to Improve Adolescent Headache Self-management
|
N/A | |
Completed |
NCT03163901 -
The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury
|
N/A | |
Completed |
NCT01664585 -
Exercise Training With Physically Active Lifestyle to Reduce Headache and Quality of Life
|
N/A | |
Completed |
NCT04632420 -
Evaluation of Headache and Childbirth in a Chronic Pain Population
|
||
Recruiting |
NCT05033613 -
Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease
|